Skip to Content

DexCom Inc DXCM Stock Quote

| Rating as of

Morningstar‘s Stock Analysis DXCM

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


DexCom's Solid Second Quarter Puts the Firm on Track to Meet Our Full-Year Expectations

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

No-moat DexCom’s second-quarter results held few surprises, and considering the firm is tracking with our full-year projections, we’re leaving our fair value estimate unchanged. After shares traded at nose-bleed levels for the last few years that we couldn’t justify with any reasonable (or even aggressive) estimates, DexCom shares have fallen to our intrinsic value, and we consider them fairly valued at this point. Now that DexCom has successfully engineered and begun commercializing its next-gen G7 continuous glucose monitor, we have greater confidence that this firm can continue innovating to remain a key competitor in the CGM market, despite considerable competitive pressure from Abbott and Medtronic. We think it’s time to revisit our thinking on DexCom’s negative moat trend and reassess the strength of the firm’s intangible assets.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DXCM

Company Profile DXCM

Business Description

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

6340 Sequence Drive
San Diego, CA, 92121
T +1 858 200-0200
Industry Medical Devices
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Speculative Growth
Employees 7,000